Ad
Saturday, 16 February 2019
Merck, Pfizer drug combo extends kidney cancer survival: study
A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment